K. Meher

Robust acidic pH and digestive enzyme stability of anti-SarsCov2 IgY antibodies: Implications for treatment of viral transmission thru gastrointestinal, ocular, nasal and skin tissues

The paper evaluates the stability of anti-SARS-CoV-2 IgY antibodies at acidic pH and against trypsin digestion, supporting their use in treating viral transmission through acidic environments.

Metformin an anti-diabetic drug, possess ACE-2 receptor-SARS- Cov-2 RBD binding antagonist activity, anti-inflammatory and cytokine inhibitory properties suitable for treatment of COVID-19

This study shows metformin blocks SARS-CoV-2 RBD-ACE2 binding, reduces inflammation, and has anti-inflammatory effects in a hamster model, suggesting it could be used as a nasal spray for COVID-19 treatment.

Targeted neutralizing IgY antibodies against SGLT1 glucose transporter reduce glucose uptake and improve glycemic profile in vivo

Nutraceutical supplement targeting multiple molecular steps synergistically enhances muscle glucose uptake and improves in vivo oral glucose disposal

This study shows a combination of vitamins improves glucose uptake and disposal in pre-diabetes and type 2 diabetes through multiple molecular targets.

A 3-Dimensional bioprinted human gut-liver axis model for studying Alcoholic Liver Disease

This study develops a 3D bioprinted gut-liver axis model to investigate how Cytolysin and ethanol together cause intestinal damage in Alcoholic Liver Disease.

Differential Activity of Repurposed Drugs as Receptor Binding Domain Antagonists for Omicron and Native Strains of SarsCov2

The paper tests repurposed drugs as antagonists of SARS-CoV-2 RBD binding, finding that iodine-containing drugs are ineffective against Omicron.

Edible formulations of chicken egg derived IgY antibodies neutralize SarsCoV2 Omicron RBD binding to human ACE2

This study develops edible IgY antibodies from chicken eggs that neutralize Omicron RBD binding to human ACE2 and formulates them into beverages for oral use.

Preparation of ingestible antibodies to neutralize the binding of SarsCoV2 RBD (receptor binding domain) to human ACE2 Receptor

This study produces chicken-derived IgY antibodies against SARS-CoV2 RBD to neutralize ACE2 binding, effective against the delta variant, and proposes their use as ingestible passive immunotherapy.

Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm

This study identifies Ertugliflozin as a potential treatment for COVID-19 through computational screening and experimental validation of its ability to inhibit RBD-ACE2 binding and modulate inflammatory responses.

Tyrosine Kinase Inhibitor Family of Drugs as Prospective Targeted Therapy for COVID-19 Based on In Silico And 3D-Human Vascular Lung Model Studies

This study evaluates four tyrosine kinase inhibitors for their anti-inflammatory and anti-thrombogenic effects against COVID-19 using in silico and 3D-human vascular lung models, suggesting they could be repurposed as targeted therapies.

In silico and in vitro Demonstration of Homoharrintonine Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model

This paper identifies Homoharringtonine as a potential repurposed drug for COVID-19 by demonstrating its ability to block RBD-ACE2 binding and show anti-inflammatory and anti-thrombogenic effects in a 3D human vascular lung model.